ACS BrightEdge Fund

BrightEdge operates at the intersection of investment and innovation to define and catalyze scientific, social, and sustainable impact across the continuum of cancer care. As the innovation and impact investment arm of the American Cancer Society (ACS), we leverage our legacy in cancer research and patient support to identify and thoughtfully invest in actionable and scalable solutions that address the most critical areas of unmet need and generate financial returns to bolster and sustain ACS’s lifesaving work for decades to come. We are not a typical investor. Given our distinct vantage and position, we are poised to lead and shape the future of cancer innovation and impact investing. Our team is purpose-built to execute BrightEdge’s integrated operating model across innovation, investment, and impact, with world-leading internal and external advisors to support mission alignment and bolster scientific and medical expertise.